Background: Methicillin-resistant Staphylococcus aureus (S.aureus) (MRSA) is a major cause of hospital acquired infections. Vancomycin is the first-line of treatment for severe MRSA infections .Elevated vancomycin MICs in MRSA are associated with a risk of vancomycin resistance development and treatment failure Objectives: This study aimed to detect MRSA, vancomycin-intermediated resistant S. aureus)VISA( and vancomycin-resistant S. aureus (VRSA) among S. aureus isolates from neonates admitted to neonatal intensive care unit (NICU) of Egypt Children's hospital for health insurance. Methodology: 91 S. aureus isolates were recovered from different clinical samples of neonates and were collected from June 2016 to February 2017 methicillin resistance detected by cefoxitin disc (30 μg) and the MIC of vancomycin was determined for MRSA isolates by using E-test. Results: (84.6%) were MRSA .The vancomycin MIC range was 0.38-4 𝜇g /mL. Two MRSA isolates (2.6 %) were VISA .No vancomycin resistance was detected. Conclusion: the MIC of vancomycin was increased but without development of vancomycin resistance, so efficient infection control measures and antibiotic policy should be adopted in hospital to avoid development of new resistant strains.